Allarity Therapeutics (ALLR) FDA Misrepresentation Case
An Allarity Therapeutics (ALLR) stockholder filed a claim against the company for misleading investors about the likelihood of FDA approval for its cancer drug, Dovitinib.
On several occasions, negative news about Allarity’s business and drug approval process caused $ALLR’s stock price to drop 36.08%, leading to significant shareholder losses.
Affected $ALLR investors may join the claim to be notified about potential recovery.
On June 30, 2022, Allarity revealed that key executives had resigned. Following this news, the stock price dropped 19.02%.
On August 2, 2022, Allarity announced that it would stop seeking FDA approval for Dovitinib as a standalone treatment. As a result, the stock fell by 3.688%.
On December 11, 2023, after further announcements regarding the termination of the CEO and CFO, Allarity's stock dropped by 13.37%.
Based on these events, $ALLR stockholders filed a claim against Allarity and its leaders, accusing them of the following:
Failing to disclose important concerns raised by the FDA about Dovitinib’s effectiveness and safety.
Misleading investors about the likelihood of Dovitinib receiving FDA approval, which caused the stock price to be artificially inflated.
Considering these accusations, investors believe Allarity misled the public about Dovitinib’s approval prospects, leading to substantial financial losses.
One of $ALLR’s investors has already filed a claim against Allarity in the U.S. District Court for the Southern District of New York.